We read with interest the narrative review by Arca et al.  on the use of headache medicines, specifically non‐steroidal anti‐inflammatory drugs (NSAIDs) and corticosteroids, amid novel coronavirus disease 2019 (COVID‐19) pandemic. Arca et al.  have comprehensively summarized current understanding of the risks and benefits of NSAIDs and corticosteroids to facilitate decision‐making by the clinicians. Nevertheless, we feel that headache medicines including the tricyclic antidepressant amitriptyline and the anticonvulsant valproate that possess the potential for weight gain are also worthy of discussion.